Quiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q Syndrome
Mission-driven investment will fund critical safety studies accelerating the path to a treatment for Dup15q syndrome. CAMBRIDGE, Mass.–(BUSINESS WIRE)–Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous…
